<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The Corventis NUVANTâ„¢ Mobile Cardiac Telemetry system is an innovative solution in the field of continuous monitoring of symptomatic and asymptomatic <z:hpo ids='HP_0001627'>cardiac abnormalities</z:hpo> to help physicians diagnose and treat non-lethal <z:hpo ids='HP_0011675'>cardiac arrhythmias</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>As an FDA cleared product on the market for more than 2 years, the collected body of patient data represents a unique and powerful source of clinical information </plain></SENT>
<SENT sid="2" pm="."><plain>Analysis of a sample of 951 NUVANT patients has revealed interesting statistics on the prevalence of various <z:hpo ids='HP_0011675'>cardiac arrhythmias</z:hpo> in the patient population </plain></SENT>
<SENT sid="3" pm="."><plain>The population is non-randomized and largely consists of US patients where a traditional Holter Monitor study was negative </plain></SENT>
<SENT sid="4" pm="."><plain>The analysis here is focused on classifying the detected <z:hpo ids='HP_0011675'>arrhythmias</z:hpo> using potential therapy solutions as a classifier </plain></SENT>
<SENT sid="5" pm="."><plain>Across the total population, 2.2% of patients presented <z:hpo ids='HP_0011675'>arrhythmias</z:hpo> indicating assessment for clinically significant <z:hpo ids='HP_0001649'>tachycardia</z:hpo>, 19% indications of potential <z:hpo ids='HP_0001662'>bradycardia</z:hpo>, 20% had indications of <z:hpo ids='HP_0005110'>atrial fibrillation</z:hpo>, 1% indicating <z:hpo ids='HP_0011675'>arrhythmias</z:hpo> requiring other conditional treatment, and 58% presenting <z:hpo ids='HP_0011675'>arrhythmias</z:hpo> likely not requiring treatment </plain></SENT>
</text></document>